

Synthesis of the C1–C12 Fragment of Calyculin C


Olga V. Konstantinova^{a,b} Ari M.P. Koskinen^{*a} 

^a Aalto University School of Chemical Engineering, Department of Chemistry and Materials Science, Kemistintie 1, P.O. Box 16100, 02150 Espoo, Finland
ari.koskinen@aalto.fi

^b Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia

Dedicated to the memory of Professor István E. Markó.

Published as part of the 50 Years SYNTHESIS – Golden Anniversary Issue



Received: 26.09.2018

Accepted after revision: 26.10.2018

Published online: 22.11.2018

DOI: 10.1055/s-0037-1610387; Art ID: ss-2018-z0654-op

License terms:    

Abstract Calyculins are a class of highly cytotoxic metabolites originally isolated from the marine sponge *Discodermia calyx*. To date, a total of twelve different calyculins (A–J) and calyculinamides (A, B and F) have been described, the most abundant (in *D. calyx*) being calyculins A and C. Herein, we demonstrate a concise route to access the C1–C12 tetraene fragment of calyculin C using transition-metal-catalyzed coupling reactions (Suzuki–Miyaura, Stille, Negishi and Heck) for the key connections. The synthesis starts from propionaldehyde and proceeds in 10 steps with 7.5% overall yield. We also describe an efficient route for the preparation of (*Z*)-3-iodobut-2-enenitrile in four steps and 68% yield.

Key words calyculins, natural products, transition-metal-catalyzed cross-coupling, Suzuki–Miyaura, Stille, Negishi and Heck coupling, syntheses of di- and polyenes

Calyculins are a class of highly cytotoxic metabolites originally isolated from the marine sponge *Discodermia calyx* by Fusetani et al.¹ Later, other marine sponges containing calyculins and calyculinamides were found.² To date, a total of twelve different calyculins (A–J) and calyculinamides (A, B and F) have been described, the most abundant (in *D. calyx*) being calyculins A and C (Scheme 1), which differ from each other only by methyl substitution at C32. The

remaining calyculins are either geometric isomers of the calyculins A or C, or close derivatives of calyculin A: calyculinamides,³ dephosphonocalyculin A,⁴ geometricin and swinhoeiamide,⁵ and clavosines A–C.⁶ Structure–activity relationships and biosyntheses of these sponge-derived cytotoxins have been reviewed.⁷

These intriguing structures have inspired several research groups to devote significant synthetic efforts toward the calyculins,⁸ and these are summarized in Table 1.


We have been involved in the development of a synthetic access to calyculins and their analogues, and our chosen retrosynthesis is shown in Scheme 1. We have so far completed the syntheses of fragments A–C,¹⁵ and have reported a synthesis of a tetraene fragment D,¹⁶ but which unfortunately is not attractive for large-scale efforts. Previous syntheses of the tetraene fragment D have been reported by Barrett,¹⁷ Shioiri¹⁸ and Armstrong.¹⁹

Transition-metal-catalyzed alkenyl–alkenyl cross-coupling reactions have proven to be effective in stereoselective syntheses of di- and polyenes and have been successfully applied to the total syntheses of a wide variety of natural products.^{20–23}

Herein, we describe our recent results on the application of Pd-catalyzed cross-coupling reactions to the synthesis of the C1–C12 tetraene fragment **D** of calyculin C. We tested the effectiveness of Stille,²⁴ Negishi,²⁵ Heck²⁶ and


Table 1 Overview of the Reported Total Syntheses of Calyculins

Group	Target	No. of steps	Overall yield	Remarks	Ref.
Evans	ent-calyculin A	33	0.54%	total synthesis	9
Masamune	calyculin A	43	0.31%	total synthesis	10
Shioiri	calyculin A	32	0.092%	formal synthesis	11
Smith	ent-calyculin A	35	0.89%	formal synthesis	12
Armstrong	calyculin C	30	0.018%	total synthesis	13
Barrett	ent-calyculin A	34	0.9%	formal synthesis	14




Scheme 1 Structures and retrosynthesis of calyculins A and C

Suzuki–Miyaura²⁷ coupling strategies for the key connections of three precursors: iodonitrile **1**, an appropriate component **2**, **3** or **4** and alcohol **5** (Scheme 2).



Scheme 2 Retrosynthetic analysis of the tetraene fragment **D** of calyculin C




Scheme 3 Synthesis of iodonitrile **1** in four steps and 68% overall yield from 2-butyne-1-ol (**6**)

The synthesis of iodonitrile **1** started with a one-pot Red-Al reduction of readily available 2-butyne-1-ol (**6**) followed by iodination to give alcohol **7**.²⁸ Oxidation of the pri-

mary alcohol **7** with MnO₂ gave aldehyde **8**, which was converted into oxime **9** (as a mixture of isomers) in 85% yield over the three steps. Initial attempts to convert **9** into iodonitrile **1** using (CF₃CO)₂O and imidazole or *N*-chlorosuccinimide and triphenylphosphine in CH₂Cl₂ proved unsuccessful. However, the desired conversion was achieved by treatment of **9** with thionyl chloride at 0 °C, providing (*Z*)-3-iodobut-2-enitrile (**1**) as the only isomer in 68% overall yield in four steps (Scheme 3). The oximes **9** and iodonitrile **1** were found to be light- and temperature-sensitive but could be stored in a freezer in darkness for a long time (a year or more).

A Stille coupling was initially attempted in order to obtain adduct **11** (Scheme 4). Stannyl derivative **2** was prepared from propargylic alcohol (**3**) by several methods: a direct stannylation reaction²⁹ with in situ generated Bu₃Sn(Bu)CuCNLi₂, a radical hydrostannylation reaction³⁰ with Bu₃SnH and AIBN at 80 °C, or a Pd(0)-catalyzed hydrostannylation reaction.³¹ Due to the formation of isomer mixtures, the yield of **2** obtained by these different methods varied from low to moderate, the best being obtained through direct stannylation. The large excess of toxic Bu₃SnH required for full conversion of substrate **3**, the low yield and the necessity to separate isomers made this approach unattractive. Therefore, the Stille coupling of iodonitrile **1** with **2**, although giving **11** stereoselectively in 39% yield, was not optimized further.


The next attempt to prepare adduct **11** was through a Negishi coupling procedure.³² This alternative shorter route



Scheme 4 Synthesis of conjugated aldehyde **12** by Stille and Negishi cross-coupling reactions

included a one-pot Schwartz hydrozirconation of **3**, transmetalation from Zr to Zn and a Pd-catalyzed cross-coupling of the vinylzinc intermediate **10** with iodonitrile **1** to provide **11** in 60% yield as a single isomer. Oxidation of **11** with MnO₂ afforded the conjugated aldehyde **12** in an excellent 90% yield (Scheme 4).

The Mizoroki–Heck cross-coupling reaction^{33a,b} is a much more attractive method providing conjugated aldehyde **12** directly from **1** in one step (Scheme 5). Unfortunately, initial experiments showed that the reaction of iodonitrile **1** with acrolein (**4**) at room temperature yielded an inseparable mixture of two isomeric compounds **12** and **13** (Table 2, entries 1–3). The isomeric compound was likely to be diene **13** because of the typical *trans* double bond coupling constant ($J = 15.8$ Hz) in the ¹H NMR spectrum and the low possibility of the formation of branched Heck coupling products with olefins containing an electron-withdrawing



Scheme 5 Mizoroki–Heck cross-coupling of iodonitrile **1** with acrolein (**4**) affording conjugated aldehyde **12**

carbonyl group, as found in acrolein. The only remaining possibility is the isomerization of the cyano group, which has been described previously.^{33c}

Some reactions (Table 2, entries 1 and 5) gave high conversions (determined from the ¹H NMR spectral data), but low isolated yields. A possible explanation is base-initiated iodine elimination in **1** and removal of volatile but-2-ynenitrile from the reaction mixture. Reaction times that were too long led to contamination of the product with polymerization or Diels–Alder cyclization by-products. After screening different catalysts and bases, we were fortunate to find conditions delivering the desired isomer **12** with 95% isomeric purity and 85% yield (entry 9). The NMR data of this product were identical with those previously obtained for compound **12** prepared via different methods (Scheme 4).

Aldehyde **12** was next subjected to the Ramirez reaction³⁴ by treatment with the ylide formed in situ from triphenylphosphine and tetrabromomethane to give dibromide **14** (Scheme 6).

A Negishi-type reaction of dibromide **14** would require iodide **15**, which was synthesized according to Scheme 7. Thus, alcohol **6** was reacted with Schwarz's reagent and then iodinated leading to iodide **21**. Silylation then gave the protected iodide **15**. However, attempts to couple **14** with the Zn reagent derived from iodide **15** in the presence of Pd(PPh₃)₄ failed.

Alternatively, the Suzuki–Miyaura coupling of dibromide **14** and olefin **16** gave the corresponding tetraene **17** (Scheme 6).³⁵ The synthesis of **16** is shown later in Scheme 11. Treatment of **17** with *t*-BuMe₂SiOTf and 2,6-lutidine in

Table 2 Conditions Screened for the Mizoroki–Heck Cross-Coupling of Iodonitrile **1** with Acrolein (**4**) Affording Conjugated Aldehyde **12**

Entry	Cat.	Base	12:13	Conversion (%) ^a	Yield (%) ^b	Time (d)
1 ^c	PdCl ₂	K ₂ CO ₃	53:47	full	36	1
2		Ag ₂ CO ₃	73:27	15	NE	1
3		KOAc	75:25	80	NE	1
4 ^d		AgOAc	95:5	12	NE	1
5			95:5	80	40	1
6	Pd ₂ (dba) ₃	AgOAc	94:6	18	NE	1
7	Pd(acac) ₂	–	–	NR	–	2
8 ^e	Pd(OAc)₂		95:5	95	65	2
9			95:5	95	85	2
10		CsOAc	82:18	99	NE	1


^a Conversions determined from the ¹H NMR spectra. NR = no reaction.

^b Yield of isolated product **12**. NE = not estimated.

^c Bu₄NF (1 equiv) was added to the reaction mixture.


^d Instead of acetonitrile the same amount of acrolein was added.

^e 10 mol% Pd(OAc)₂ was used.




Scheme 6 Synthesis of tetraene **20** synthesis according to the first strategic plan

dichloromethane at $-85\text{ }^{\circ}\text{C}$ led to the protected compound **18** in 91% yield along with a small amount of cyclized compound **19**. Unfortunately, compound **18** showed a tendency to undergo spontaneous cyclization to give compound **19** during column chromatography or on standing in solution at room temperature. This type of Pd-catalyzed cyclization of conjugated tetraenes has been reported by Parker,³⁶ Trauner³⁷ and Baldwin.³⁸ Finally, the bromotetraene **18** was subjected to a Negishi cross-coupling using ZnMe_2 and $[\text{Pd}(t\text{-Bu}_3\text{P})_2]$ ³⁹ to give tetraene **20**.




Scheme 7 Synthesis of iodide **15**

As the approach to tetraene **20** was significantly complicated by the undesired formation of the cyclic compound **19**, modifications according to Scheme 8 were undertaken to avoid the undesired cyclization.



Scheme 8 Modified retrosynthetic analysis of tetraene fragment **D**

The synthesis of the key compound **5** started with self-aldol condensation of propionaldehyde (**23**) catalyzed by 4-*trans*-hydroxy-L-proline in DMSO⁴⁰ to give **24** as a 6:1 *anti/syn* diastereomeric mixture (determined by ^1H NMR) (Scheme 9). Unfortunately, the next step, silylation with *tert*-butyldimethylsilyl triflate and diisopropylethylamine in dichloromethane at $0\text{ }^{\circ}\text{C}$, was accompanied by partial racemization at the labile α -stereogenic center leading to




Scheme 9 Synthetic route to **29** representing key compound **5**


compound **25** in 76% yield (2 steps from **23**), but a diastereomeric ratio of 2:1 (*anti/syn*). The protected compound **25** was subjected to the Ramirez reaction and the dibromoolefins **26** and **27** were separated through column chromatography on silica gel to afford the desired diastereomer **26** as the major product. Dibromide **26** was then subjected to a Corey–Fuchs alkylation step.⁴¹ Thus, elimination with *n*-butyllithium and methylation with iodomethane gave intermediate **28** in excellent yield. Sequential hydrozirconation of **28** with Schwartz's reagent⁴² (obtained in situ from Cp_2ZrCl_2 and DIBAL-H) and iodination afforded iodide **29** in 65% yield.

The enantiomeric composition of the obtained chiral compounds was determined according to the Mosher method.⁴³ Deprotection of **26** with $n\text{-Bu}_4\text{NF}$ at $45\text{--}50\text{ }^{\circ}\text{C}$ proceeded with dehydrobromination leading to monobromo-substituted **30**. Improved results were obtained when **28** was deprotected under the same conditions to give the more stable compound **31** (Scheme 10), which was then subjected to derivatization with Mosher's acid chlorides.⁴⁴ NMR analysis established a 70% enantiomeric excess for alkyne **28** (see the Supporting Information).

Only a few approaches to the *anti* diastereomer of **24** or its precursors with high de and ee values, requiring multi-step syntheses, are described.⁴⁵ When we first tested the key steps of the approach (see Scheme 8), we gave preference to the shorter synthetic route to compound **29** with lower ee over the longer synthetic route with higher ee.




Scheme 10 Synthesis of compounds for derivatization with Mosher's acid chlorides to establish the enantiomeric excesses of their precursors



Scheme 11 Syntheses of the components for transition-metal-catalyzed cross-coupling reactions with iodide **29**

In multistep syntheses a convergent strategy is much more advantageous over a linear one. We therefore prepared three compounds, **32**,²⁹ **16**⁴⁶ and **21**, and planned to modify them according to Scheme 11. A further intention was the Heck coupling of the obtained diene with **1** and final assembly of the resulting triene with key compound **5** (i.e., vinyl iodide **29**) in the last step.

Only the tin derivative **34** was obtained with a satisfactory yield according to this scheme. All attempts to convert **34** into compound **37** by metathesis with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane led to complex reaction mixtures with low yields of **37** (Scheme 12). The reaction of **34** with **1** resulted in formation of the Stille coupling product instead of the desired Heck coupling product.




Conditions:
Hoveyda–Grubbs 1st generation, CH₂Cl₂, 40 °C
or Hoveyda–Grubbs 2nd generation, CH₂Cl₂, 35 °C
or Hoveyda–Grubbs 1st generation, CH₂Cl₂, r.t.
or Grubbs 1st generation, CH₂Cl₂, r.t.

Scheme 12 Screened conditions for metathesis reactions of **34** with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane

The Pd(PPh₃)₄-catalyzed Suzuki–Miyaura coupling of vinylboronate **16** with iodide **29** proceeded stereoselectively with 95% yield to give the conjugated diene **38** with two tri-substituted double bonds (Scheme 13). Oxidation with MnO₂ afforded aldehyde **39**, which was subjected to Wittig olefination to yield the conjugated triene **40**.

Inspired by the successful Mizoroki–Heck coupling of **1** with acrolein (**4**) (see Scheme 5), we first tried to apply the same conditions to couple triene **40** with iodonitrile **1** (Scheme 14). As AgOAc had demonstrated the best stereoselectivity in this reaction, we opted for AgOAc as the base again and no other bases were tested. However, the best conditions from Table 2 were not a guarantee of the desired result for the reaction of iodonitrile **1** with triene **40**. All experiments yielded a mixture of isomers, which were not separated into individual components. One of the compo-




Scheme 13 Synthetic route to triene **40**

nents was tetraene **41**, the ¹H NMR data of which were identical to those of the same compound obtained later through Suzuki–Miyaura coupling according to Scheme 15. Analysis of the spectral data of the second component most likely showed the formation of isomer **42** instead of **43**.

Despite the lack of high stereoselectivity this reaction is interesting because, to the best of our knowledge, it is one of only a few examples of the Heck coupling of vinyl halides with nonaromatic trienes.⁴⁷


Metathesis of **40** with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane in dichloromethane at room temperature gave triene **45** (Scheme 15), which was reacted with iodo-



Conditions: catalyst (10 mol%)
AgOAc (3 equiv), MeCN, 21–24 h

Catalyst	T, (°C)	41:42
Pd(OAc) ₂	r.t.	–
Pd(OAc) ₂	30	72:28
Pd(OAc) ₂	85–90	complex mixture
PdCl ₂	37	58:42

Scheme 14 Mizoroki–Heck cross-coupling reaction of triene **40** with iodide **1**



Scheme 15 Final steps in the synthesis of tetraene **41** according to the second strategic plan

nitrile **1** via a Suzuki–Miyaura coupling to afford the desired tetraene **41**. The chemical shifts and coupling constants in the ^1H NMR of the obtained tetraene **41** matched very well with the same parameters described previously for an analogous tetraene fragment.⁴⁸

In summary, we have demonstrated a concise route to access the C1–C12 tetraene fragment **41** of calyculin C. The synthesis starts from propionaldehyde (**23**) and proceeds in 10 steps with 7.5% overall yield. We have also described an efficient route for the preparation of (*Z*)-3-iodobut-2-enitrile (**1**) in four steps and 68% overall yield.

Moisture-sensitive reactions were carried out under an argon atmosphere, and glassware was flame-dried under high vacuum or in an oven. Dry solvents (THF, Et₂O, toluene, MeCN, CH₂Cl₂) were obtained using an MBraun MB-SPS 800 solvent drying system. Commercial reagents were used without further purification. Ph₃P was recrystallized from hot ethanol and was dried over P₂O₅ under vacuum. *n*-BuLi was titrated with *N*-benzylbenzamide. Other solvents and reagents were used as received. Analytical TLC was performed using Merck silica gel (60, F254 230–400 mesh) precoated aluminum plates and samples were made visual by UV light ($\lambda = 250$ nm) and/or staining upon heating with standard KMnO₄, anisaldehyde or PMA solutions. Flash chromatography was carried out using Merck silica gel (60, F254 230–400 mesh) and p.a. grade solvents. IR spectra were recorded with Perkin-Elmer ONE FTIR or Bruker ALPHA ECO ATR FTIR spectrometers. ^1H and ^{13}C NMR spectra were recorded with a Bruker Avance DPX-400 spectrometer (^1H : 400 MHz; ^{13}C : 101 MHz). The chemical shifts are reported in ppm relative to TMS as the internal standard ($\delta = 0.00$) or the residual solvent signal (^1H NMR: CDCl₃, $\delta = 7.26$; ^{13}C NMR: CDCl₃, $\delta = 77.16$). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). HRMS were obtained using a Waters Micromass LCT Premier (ESI) spectrometer.

(*Z*)-3-Iodobut-2-enitrile (**1**)

To a solution of oxime **9** (0.5 g, 2.4 mmol) in THF (8 mL) cooled to -5 °C under an inert atmosphere was added dropwise SOCl₂ (0.26 mL, 3.6 mmol) and the resulting mixture was stirred for 30 min. It was then poured into a saturated aqueous solution of ice-cold NaHCO₃ and extracted with CH₂Cl₂. The combined organic extracts were dried over Na₂SO₄, filtered and concentrated under reduced pressure (140 mbar) without heating. The residue was purified by column chromatography on silica gel (PE/Et₂O, 40:1 to 15:1) to give compound **1** (0.36 g, 80%) as a colorless oil.

IR (thin film): 3397, 2975, 2937, 2226, 1614, 1461, 1364, 1272, 1178, 1101, 838, 793 cm⁻¹.

^1H NMR (400 MHz, CDCl₃): $\delta = 6.13$ (q, $J = 1.6$ Hz, 1 H), 2.68 (d, $J = 1.6$ Hz, 3 H).

^{13}C NMR (101 MHz, CDCl₃): $\delta = 122.84, 118.21, 110.28, 34.72$.

HRMS (ESI): m/z [M + Na]⁺ calcd for C₄H₄NNa: 215.9286; found: 215.9283.

(*E*)-3-(Tributylstannyl)prop-2-en-1-ol (**2**)

Stannylation of propargylic alcohol (**3**) with in situ generated Bu₃Sn(Bu)CuCNLi₂ was performed according to the reported procedure.[29]

(*Z*)-3-Iodobut-2-en-1-ol (**7**)

A solution of Red-Al® (65% in toluene, 9 mL, ≈ 3.5 M, 31.5 mmol) was added dropwise over 1 h to a solution of 2-butyne-1-ol (**6**) (1.59 g, 22.7 mmol) in dry Et₂O (35 mL) at 0 °C under an inert atmosphere. The reaction mixture was allowed to warm slowly to r.t. and was stirred at ambient temperature overnight. After the starting material had been completely consumed (TLC monitoring), the mixture was cooled to 0 °C and EtOAc (1.8 mL) was added dropwise. The mixture was then cooled to -78 °C and a solution of I₂ (8.65 g, 34.1 mmol) in THF (25 mL) was added dropwise over 1.5 h. After 30 min, the cooling bath was removed and stirring was continued at r.t. for 1 h. The mixture was then poured into an ice-cold saturated aqueous solution of Na₂S₂O₃ and extracted with Et₂O. The combined organic fractions were dried over Na₂SO₄, filtered and concentrated under reduced pressure (50 mbar) without heating to give 4.5 g (quant.) of crude compound **7** as a colorless oil, which was used in the next step without purification. Pure compound **7** was obtained by column chromatography on silica gel (hexane/EtOAc, 5:1). The spectroscopic data are consistent with reported literature data.[49,50]

(*ZZ*)-3-Iodobut-2-enal Oxime (**9**)

To a solution of alcohol **7** (4.5 g) in CH₂Cl₂ (100 mL) was added MnO₂ (22 g, 253 mmol) portionwise. When the reaction was complete, the MnO₂ was removed by filtration through a pad of Celite® and the pad was rinsed with CH₂Cl₂. The filtrate was concentrated under reduced pressure (250 mbar) without heating. The residue was dissolved in THF (30 mL) and NH₂OH·HCl (1.9 g, 27.3 mmol), H₂O (7 mL) and NaHCO₃ (1.9 g, 22.7 mmol) were added portionwise. The reaction mixture was stirred at r.t. for 20 min and then poured into a saturated aqueous solution of NaHCO₃ and extracted with CH₂Cl₂. The combined organic fractions were dried over Na₂SO₄, filtered, and concentrated under vacuum without heating. The residue was purified by column chromatography on silica gel (hexane/Et₂O, 40:1 to 20:1) to

give **9** as a slightly yellow solid [4.0 g, 84% from 2-butyne-1-ol (**6**)]. This compound was very light-sensitive and should be stored in a freezer at $-18\text{ }^{\circ}\text{C}$ in the dark.

IR (thin film): 3160, 3042, 2865, 2772, 1633, 1478, 1423, 1309, 1261, 1080, 1015, 974, 934, 839, 726 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 9.92 (br s, 1 H), 7.87 (d, J = 9.1 Hz, 0.62 H), 7.20 (d, J = 8.5 Hz, 0.34 H), 6.87 (d, J = 8.5 Hz, 0.34 H), 6.28 (dd, J = 9.1, 1.4 Hz, 0.64 H), 2.71 (d, J = 1.5 Hz, 1.05 H), 2.66 (s, 1.93 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 154.96, 150.91, 127.86, 122.84, 113.02, 109.22, 35.33, 34.95.

HRMS (ESI): m/z [$M + \text{Na}$] $^+$ calcd for $\text{C}_4\text{H}_6\text{NONa}$: 233.9392; found: 233.9383.

(2Z,4E)-6-Hydroxy-3-methylhexa-2,4-dienitrile (**11**) (1st Method)

A mixture of iodide **1** (80 mg, 0.4146 mmol), stannyl derivative **2** (140 mg, 0.4146 mmol) and $\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ (11 mg, 0.0414 mmol, 0.1 equiv) in THF (1.5 mL) and DMF (1.5 mL) was heated at $80\text{ }^{\circ}\text{C}$ under argon for 22 h. The reaction mixture was poured into a saturated solution of brine and extracted with EtOAc. The combined organic fractions were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography on silica gel (hexane/EtOAc, 10:1 to 1:3) to give adduct **11** as a colorless oil (20 mg, 39%).

(2Z,4E)-6-Hydroxy-3-methylhexa-2,4-dienitrile (**11**) (2nd Method)

The adduct **11** was also obtained by a slightly modified procedure.[32] Under argon at $0\text{ }^{\circ}\text{C}$, DIBAL-H (0.62 mL, 1 M in hexane, 0.62 mmol, 1.5 equiv) was added slowly via syringe to a solution of alcohol **3** (35 mg, 0.62 mmol, 1.5 equiv) in THF (0.3 mL) and the resulting solution was allowed to warm to r.t. and stirred for 1 h. In another flask covered with aluminum foil under argon were added Cp_2ZrCl_2 (363 mg, 1.24 mmol, 3 equiv) and THF (2 mL). To this mixture was added dropwise DIBAL-H (1.24 mL, 1 M in hexane, 1.24 mmol, 3 equiv) at $0\text{ }^{\circ}\text{C}$. After 30 min, the pretreated alcohol mixture was transferred via cannula into the second reaction flask and the resulting mixture was stirred at r.t. for 2 h until all the solid had dissolved. Next, a solution of ZnBr_2 (280 mg, 1.24 mmol, 3 equiv) in THF (1.5 mL) was added via cannula. After 15 min, a solution of **1** (80 mg, 0.41 mmol, 1 equiv) and $\text{Pd}(\text{PPh}_3)_4$ (48 mg, 0.04 mmol, 0.1 equiv) in THF (0.9 mL) was transferred via cannula and the reaction mixture was left stirring overnight. The mixture was diluted with Et_2O and quenched with saturated NH_4Cl solution. The mixture was then extracted with Et_2O and the combined organic layers were dried over Na_2SO_4 , filtered and concentrated under vacuum. The residue was purified by column chromatography on SiO_2 (PE/ Et_2O , 30:1 to 1:10) to give **11** as a colorless oil (37 mg, 60%).

IR (thin film): 3412, 2212, 1643, 1585, 1436, 1097, 965 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 6.86 (dt, J = 15.7, 1.7 Hz, 1 H), 6.27 (dtd, J = 15.7, 5.1, 0.5 Hz, 1 H), 5.20–5.14 (m, 1 H), 4.34 (dd, J = 5.1, 1.3 Hz, 2 H), 2.02 (d, J = 1.4 Hz, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 156.06, 137.92, 127.44, 116.80, 96.53, 62.84, 19.61.

HRMS (ESI): m/z [$M + \text{Na}$] $^+$ calcd for $\text{C}_7\text{H}_9\text{NONa}$: 146.0582; found: 146.0582.

(2Z,4E)-3-Methyl-6-oxohexa-2,4-dienitrile (**12**) (1st Method)

To a solution of alcohol **11** (18 mg, 0.15 mmol, 1 equiv) in CH_2Cl_2 (1 mL) was added MnO_2 (190 mg, 2.19 mmol, 15 equiv) portionwise and the resulting mixture was stirred at r.t. When the reaction was com-

plete, MnO_2 was removed by filtration through a pad of Celite[®] and the pad was rinsed with CH_2Cl_2 . The filtrate was concentrated under vacuum to give **12** as a colorless oil (16 mg, 90%).

(2Z,4E)-3-Methyl-6-oxohexa-2,4-dienitrile (**12**) (2nd Method)

To a solution of **1** (97 mg, 0.50 mmol, 1 equiv) in MeCN (2 mL) covered with aluminum foil were added acrolein (**4**) (0.33 mL, 5.03 mmol, 10 equiv), $\text{Pd}(\text{OAc})_2$ (6 mg, 0.025 mmol, 5 mol%) and AgOAc (100 mg, 0.60 mmol, 1.2 equiv) and reaction mixture was stirred under argon in the dark for 48 h at r.t. The mixture was filtered through a pad of SiO_2 , the pad was rinsed with Et_2O and the filtrate was concentrated under vacuum. The residue was purified by column chromatography on SiO_2 (hexane/ Et_2O , 15:1 to 1:1) to give **12** (52 mg, 85%).

IR (thin film): 2217, 1682, 1132, 985, 862 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 9.77 (d, J = 7.6 Hz, 1 H), 7.63 (dd, J = 15.9, 0.5 Hz, 1 H), 6.43 (ddd, J = 15.8, 7.6, 0.4 Hz, 1 H), 5.56–5.57 (m, 1 H), 2.13 (d, J = 1.5 Hz, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 193.26, 153.77, 146.04, 134.39, 115.47, 104.55, 19.36.

HRMS (ESI): m/z [$M + \text{Na}$] $^+$ calcd for $\text{C}_7\text{H}_7\text{NONa}$: 144.0425; found: 144.0422.

(2Z,4E)-7,7-Dibromo-3-methylhepta-2,4,6-trienitrile (**14**)

To a solution of Ph_3P (2.2 g, 8.59 mmol, 8 equiv) in dry CH_2Cl_2 (20 mL) cooled to $0\text{ }^{\circ}\text{C}$ under an inert atmosphere was added a solution of CBr_4 (306 mg, 4.29 mmol, 4 equiv) in dry CH_2Cl_2 (5 mL). After 10 min, the mixture turned yellow and was cooled to $-50\text{ }^{\circ}\text{C}$. A solution of aldehyde **12** (130 mg, 1.07 mmol, 1 equiv) in dry CH_2Cl_2 (1 mL) was added dropwise at the same temperature. The mixture was then allowed to warm to r.t. over 2 h until the reaction was complete. Hexane was added and the obtained precipitate was removed by filtration. The filtrate was concentrated under vacuum and the residue was purified by column chromatography on silica gel (hexane) to give dibromide **14** (180 mg, 61%) as a white solid.

IR (thin film): 2211, 1603, 1548, 1440, 1354, 1211, 962, 806 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.13 (dd, J = 10.4, 0.6 Hz, 1 H), 6.94 (d, J = 15.4 Hz, 1 H), 6.58 (ddd, J = 15.3, 10.4, 0.4 Hz, 1 H), 5.29 (d, J = 0.5 Hz, 1 H), 2.08 (d, J = 1.2 Hz, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 155.43, 136.30, 132.47, 131.87, 116.69, 98.91, 97.29, 19.28.

HRMS (ESI): m/z [$M + \text{Na}$] $^+$ calcd for $\text{C}_8\text{H}_7\text{NNaBr}_2$: 297.8843; found: 297.8854.

(E)-tert-Butyl[(3-iodobut-2-en-1-yl)oxy]dimethylsilane (**15**)

To a solution of iodide **21** (156 mg, 0.79 mmol, 1 equiv) in dry CH_2Cl_2 (3 mL) at $-78\text{ }^{\circ}\text{C}$ were added dropwise $t\text{-BuMe}_2\text{SiOTf}$ (0.27 mL, 1.18 mmol, 1.5 equiv) and 2,6-lutidine (0.27 mL, 1.18 mmol, 3 equiv) and the resulting mixture was stirred for 1 h. The reaction was quenched with saturated NaHCO_3 solution, allowed to warm to r.t. and extracted with CH_2Cl_2 . The combined organic fractions were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ Et_2O , 30:1) to give **15** (236 mg, 96%) as a colorless oil.

^1H NMR (400 MHz, CDCl_3): δ = 6.30 (tq, J = 6.5, 1.5 Hz, 1 H), 4.12 (ddd, J = 6.5, 1.8, 0.8 Hz, 2 H), 2.41 (dt, J = 1.6, 0.9 Hz, 3 H), 0.90 (s, 9 H), 0.07 (s, 6 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 140.80, 96.14, 60.82, 28.23, 26.03, 18.49, -5.06 .

The data are consistent with those reported in the literature.[51]

(Z)-3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)but-2-en-1-ol (16)

The product **16** (0.5 g, 69% yield) was obtained from 2-butyne-1-ol (**6**) (253 mg, 3.58 mmol) according to the literature procedure.[46]

(2Z,4E,6Z,8E)-7-Bromo-10-hydroxy-3,8-dimethyldeca-2,4,6,8-tetraenitrile (17)

To a solution of **16** (56 mg, 0.28 mmol, 1.1 equiv) in degassed THF (0.45 mL) under an argon atmosphere was added TIOEt (0.018 mL, 0.25 mmol, 1 equiv) followed by H₂O (0.04 mL) and the resulting mixture was stirred at r.t. for 5 min. A solution of **14** (70 mg, 0.25 mmol, 1 equiv) and Pd(PPh₃)₄ (15 mg, 0.013 mmol, 0.05 equiv) in THF (1 mL) was added and the mixture was stirred at r.t. for 4 h. After filtration through a pad of Celite® and Na₂SO₄, the filtrate was concentrated under vacuum and the residue purified by column chromatography on SiO₂ (hexane/Et₂O, 60:1 to 2:1) to give: (1) dibromide **14** (22 mg, 31%), and (2) adduct **17** (43 mg, 63%), which was isolated crude and used in the next step without purification.

(2Z,4E,6Z,8E)-7-Bromo-10-[(tert-butyl dimethylsilyloxy)-3,8-dimethyldeca-2,4,6,8-tetraenitrile (18) and (2Z,4Z,6E)-6-Bromo-8-[(tert-butyl dimethylsilyloxy)methyl]-2,7-dimethylcycloocta-2,4,6-triene-1-carbonitrile (19)

A solution of **17** (40 mg, 0.15 mmol, 1 equiv) in CH₂Cl₂ (1.5 mL) was cooled to -85 °C under an argon atmosphere and 2,6-lutidine (0.05 mL, 0.45 mmol, 3 equiv) was added, followed by the addition of *t*-BuMe₂SiOTf (0.05 mL, 0.22 mmol, 1.5 equiv). The mixture was stirred at this temperature for 1 h and then quenched by the addition of brine. The mixture was allowed to warm to r.t. and then extracted with Et₂O, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by column chromatography on SiO₂ (hexane/Et₂O, 100:1 to 35:1) to give tetraenitrile **18** (52 mg, 91%) and cyclized compound **19** (5 mg, 8%).

Compound 18

IR (thin film): 2952, 2929, 2884, 2856, 2209, 1595, 1253, 1105, 1070, 834, 769 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.04 (dt, *J* = 29.7, 12.5 Hz, 2 H), 6.71 (d, *J* = 9.7 Hz, 1 H), 6.31 (t, *J* = 5.6 Hz, 1 H), 5.20 (d, *J* = 1.1 Hz, 1 H), 4.40 (d, *J* = 5.9 Hz, 2 H), 2.10 (d, *J* = 1.4 Hz, 3 H), 1.92 (d, *J* = 0.9 Hz, 3 H), 0.91 (s, 9 H), 0.09 (s, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 156.17, 136.57, 135.30, 134.05, 132.80, 132.13, 127.02, 117.05, 97.39, 61.13, 26.05, 19.39, 18.47, 15.39, -5.01.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₈H₂₈NONaSiBr: 404.1021; found: 404.1035.

Compound 19

IR (thin film): 2954, 2929, 2885, 2857, 1471, 1256, 1100, 837, 778 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 6.65 (dd, *J* = 14.1, 11.2 Hz, 1 H), 6.28 (d, *J* = 14.0 Hz, 1 H), 6.04 (d, *J* = 11.1 Hz, 1 H), 4.02 (t, *J* = 9.8 Hz, 1 H), 3.94 (dd, *J* = 10.1, 5.1 Hz, 1 H), 3.79–3.68 (m, 2 H), 2.00 (s, 6 H), 0.93 (s, 9 H), 0.14 (s, 3 H), 0.13 (s, 3 H).

¹³C NMR (101 MHz, CDCl₃): δ = 133.75, 132.28, 131.59, 130.21, 128.69, 127.06, 119.46, 62.33, 50.93, 39.44, 25.99, 19.65, 18.38, 17.21, -5.19, -5.25.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₈H₂₈NONaSiBr: 404.1021; found: 404.1031.

(2Z,4E,6E,8E)-10-[(tert-Butyldimethylsilyloxy)-3,7,8-trimethyldeca-2,4,6,8-tetraenitrile (20)

To a solution of Pd(*t*-Bu₃P)₂ (4 mg, 0.008 mmol, 0.1 equiv) in THF (0.4 mL) at 0 °C was added ZnMe₂ (0.16 mL, 0.32 mL, 4 equiv). The obtained solution was transferred via cannula to neat **18** (31 mg, 0.08 mmol, 1 equiv) which had been cooled to 0 °C under argon. The resulting mixture was stirred at 0 °C for 4 h and then quenched with a saturated aqueous solution of NaHCO₃ and extracted with CH₂Cl₂. The combined organic fractions were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by column chromatography on SiO₂ (hexane/Et₂O, 60:1 to 40:1) to give **20** (11 mg, 42%).

IR (thin film): 2954, 2929, 2856, 2209, 1593, 1255, 1094, 1050, 960, 836 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 6.99 (dd, *J* = 15.0, 11.0 Hz, 1 H), 6.85 (d, *J* = 15.0 Hz, 1 H), 6.38 (d, *J* = 11.0 Hz, 1 H), 5.86 (t, *J* = 5.6 Hz, 1 H), 5.09 (s, 1 H), 4.40 (d, *J* = 5.8 Hz, 2 H), 2.07 (d, *J* = 1.3 Hz, 3 H), 2.02 (s, 3 H), 1.84 (d, *J* = 0.8 Hz, 3 H), 0.92 (s, 9 H), 0.09 (s, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 156.64, 143.16, 135.98, 133.59, 130.57, 129.45, 125.30, 117.50, 95.44, 61.43, 26.13, 19.57, 18.56, 14.69, 14.31, -4.95.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₉H₃₁NONaSi: 340.2073; found: 340.2077.

(E)-3-Iodobut-2-en-1-ol (21)

Under argon at 0 °C, DIBAL-H (4.28 mL, 1 M in hexane, 4.28 mmol, 1 equiv) was added slowly via syringe to a solution of but-2-yn-1-ol (**6**) (300 mg, 4.28 mmol, 1 equiv) in THF (0.3 mL) and the solution was then allowed to warm to r.t. and stirred for 1 h. To another flask covered with aluminum foil under argon were added Cp₂ZrCl₂ (2.5 g, 8.56 mmol, 2 equiv) and THF (15 mL). To this suspension was added dropwise DIBAL-H (8.6 mL, 1 M in hexane, 8.6 mmol, 2 equiv) at 0 °C. After 30 min, the pretreated alcohol mixture was transferred via cannula into the second reaction flask and the resulting mixture was stirred at 40 °C for 3.5 h until all the solid had dissolved. Next, the mixture was cooled to 0 °C and treated with a solution of I₂ (2.4 g, 9.42 mmol, 2.2 equiv) in THF (5 mL). After stirring at 0 °C for 15 min, the mixture was diluted with Et₂O and quenched with saturated Na₂S₂O₃ solution. The mixture was extracted with Et₂O and the combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on SiO₂ (hexane/Et₂O, 40:1 to 3:1) to give **21** (402 mg, 47%).

¹H NMR (400 MHz, CDCl₃): δ = 6.44–6.38 (m, 1 H), 4.09 (t, *J* = 6.0 Hz, 2 H), 2.45 (d, *J* = 0.7 Hz, 3 H), 1.46 (br s, 1 H).

¹³C NMR (101 MHz, CDCl₃): δ = 139.85, 98.71, 60.10, 28.16.

The data are consistent with those reported in the literature.⁵²

3-Hydroxy-2-methylpentanal (24)

The product was obtained by the 4-*trans*-hydroxy-L-proline-catalyzed aldol reaction of propionaldehyde in DMSO at 4 °C.⁴⁰

3-[(tert-Butyldimethylsilyloxy)-2-methylpentanal (25)

To a solution of aldehyde **24** (0.5 g, 4.3 mmol) and DIPEA (3.2 mL, 18.4 mmol) in dry CH₂Cl₂ (20 mL) cooled to -5 °C was added *t*-BuMe₂SiOTf (3 mL, 13.1 mmol) dropwise and stirring was continued for 1 h. During this time the temperature rose to 0 °C, and at this point the reaction was quenched with saturated NaHCO₃ solution and extracted

with CH_2Cl_2 . The combined organic fractions were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure without heating. The residue was purified by column chromatography on silica gel (hexane/ Et_2O , 40:1 to 16:1) to give **25** (0.97 g, 98%) as a colorless oil.

IR (thin film): 2958, 2931, 2858, 1726, 1463, 1253, 833, 773, 668 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 9.74 (dd, J = 7.3, 1.7 Hz, 1 H), 4.02 (td, J = 6.6, 3.7 Hz, 0.5 H), 3.85 (q, J = 5.5 Hz, 0.5 H), 2.55–2.40 (m, 1 H), 1.63–1.42 (m, 2 H), 1.05 (d, J = 7.0 Hz, 1.5 H), 1.04 (d, J = 6.9 Hz, 1.5 H), 0.92–0.87 (m, 3 H), 0.86 (s, 4.5 H), 0.85 (s, 4.5 H), 0.05 (s, 3 H), 0.04 (s, 1.5 H), 0.02 (s, 1.5 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 205.50, 205.27, 74.65, 73.49, 50.93, 50.71, 27.58, 27.53, 25.89, 25.88, 18.16, 18.14, 10.61, 10.22, 9.03, 7.66, –4.11, –4.16, –4.68.

tert-Butyl[(6,6-dibromo-4-methylhex-5-en-3-yl)oxy]dimethylsilane (anti-26) and tert-Butyl[(6,6-dibromo-4-methylhex-5-en-3-yl)oxy]dimethylsilane (syn-27)

To a solution of Ph_3P (11.4 g, 43.4 mmol) in dry CH_2Cl_2 (40 mL) cooled to -15°C under an inert atmosphere was added a solution of CBr_4 (1.55 g, 21.7 mmol, 5.6 equiv) in dry CH_2Cl_2 (5 mL). After 5 min, the reaction mixture turned yellow and a solution of aldehyde **25** (0.9 g, 3.9 mmol) in dry CH_2Cl_2 (5 mL) was added dropwise. Over the next 2 h the mixture was allowed to warm to r.t. until the reaction was complete. Hexane was added and the obtained precipitate was removed by filtration. The filtrate was concentrated under vacuum and the residue was purified by column chromatography on silica gel (hexane) to give a mixture of two diastereomers **26** and **27** (1.00 g, 67%) as a colorless oil. These two diastereomers were partly separated by consecutive column chromatography on silica gel (hexane) to give the individual diastereomers.

anti-26

IR (thin film): 2958, 2930, 2857, 1461, 1255, 1109, 1079, 1038, 872, 834, 773 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 6.37 (d, J = 9.5 Hz, 1 H), 3.49 (ddd, J = 6.7, 5.9, 3.5 Hz, 1 H), 2.61 (m, 1 H), 1.51–1.31 (m, 2 H), 1.01 (d, J = 6.9 Hz, 3 H), 0.90 (s, 9 H), 0.87 (t, J = 7.5 Hz, 3 H), 0.06 (s, 3 H), 0.05 (s, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 140.96, 88.04, 76.27, 42.86, 28.14, 26.05, 18.25, 15.97, 10.01, –4.06, –4.38.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{13}\text{H}_{26}\text{ONaSiBr}_2$: 407.0017; found: 407.0003.

syn-27

IR (thin film): 2957, 2929, 2857, 1462, 1377, 1255, 1014, 873, 833, 773.

^1H NMR (400 MHz, CDCl_3): δ = 6.32 (d, J = 9.5 Hz, 1 H), 3.56 (dd, J = 11.1, 5.5 Hz, 1 H), 2.64–2.49 (m, 1 H), 1.58–1.37 (m, 2 H), 0.97 (d, J = 6.8 Hz, 3 H), 0.90 (s, 9 H), 0.88 (m, 3 H), 0.05 (s, 3 H), 0.05 (s, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 142.65, 87.58, 75.45, 42.37, 27.64, 26.03, 18.27, 13.25, 9.63, –4.09, –4.50.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{13}\text{H}_{26}\text{ONaSiBr}_2$: 407.0017; found: 407.0000.

tert-Butyldimethyl[(3S,4R)-4-methylhept-5-en-3-yl]oxy)silane (28)

To a solution of dibromide **26** (0.4 g, 1.0 mmol) in THF (5 mL) at -78°C was added $n\text{-BuLi}$ (1.66 mL, 2 M in hexane, 3.3 mmol, 3.3 equiv) dropwise. The reaction mixture was allowed to warm to -50°C

over 20 min at which point TLC indicated that no dibromide **26** remained. The mixture was cooled to -78°C and MeI (0.2 mL, 3.1 mmol, 3.1 equiv) was added dropwise. The mixture was allowed to warm to -45°C over 15 min at which point the reaction was complete. The cooling bath was removed and the mixture was allowed to warm to r.t., poured into saturated NH_4Cl solution and extracted with CH_2Cl_2 . The combined organic fractions were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure without heating. The residue was purified by column chromatography on silica gel ($\text{PE}/\text{Et}_2\text{O}$, 90:1) to give **28** (230 mg, 92%).

IR (thin film): 2958, 2930, 2857, 1253, 1107, 1063, 871, 832, 771 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 3.56 (dt, J = 8.2, 4.1 Hz, 1 H), 2.49–2.57 (m, 1 H), 1.78 (d, J = 2.4 Hz, 3 H), 1.72–1.60 (m, 1 H), 1.47–1.35 (m, 1 H), 1.08 (d, J = 7.1 Hz, 3 H), 0.95–0.84 (m, 12 H), 0.05 (s, 6 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 81.79, 76.82, 76.35, 32.25, 26.02, 25.61, 18.28, 15.30, 10.63, 3.70, –4.35.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{14}\text{H}_{28}\text{ONaSi}$: 263.1807; found: 263.1795.

tert-Butyl[(3S,4R,E)-6-iodo-4-methylhept-5-en-3-yl]oxy]dimethylsilane (29)

Under argon at 0°C , DIBAL-H (0.07 mL, 1 M in cyclohexane, 0.07 mmol, 0.3 equiv) was added slowly via syringe to a solution of **28** (60 mg, 0.25 mmol, 1 equiv) in THF (1 mL). The solution was allowed to warm to r.t. and stirred for 1 h. To another flask covered with aluminum foil under argon were added Cp_2ZrCl_2 (182 mg, 0.62 mmol, 2.5 equiv) and THF (1.5 mL). To this suspension was added dropwise DIBAL-H (0.62 mL, 1 M in cyclohexane, 0.62 mmol, 2.5 equiv) at 0°C . After 50 min, the pretreated solution of **28** was transferred via cannula into the second reaction flask, the cooling bath was removed and the mixture was allowed to warm to r.t. and then stirred at 40°C for 1 h until all the solid had dissolved. The mixture was cooled to -78°C and treated with a solution of I_2 (158 mg, 0.62 mmol, 2.5 equiv) in THF (1 mL) until the iodine color was persistent. After 5 min, the cooling bath was removed, and the mixture was allowed to warm to r.t. and then quenched with a minimum amount of aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution, dried over Na_2SO_4 and filtered through a Celite® pad. The pad was rinsed with Et_2O and the filtrate was concentrated under vacuum. The residue was purified by column chromatography on silica gel (hexane) to give **29** (60 mg, 65%) as a colorless oil.

IR (thin film): 2958, 2929, 2856, 1377, 1251, 1023, 1005, 832, 772 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 6.07 (d, J = 10.0 Hz, 1 H), 3.37–3.45 (m, 1 H), 2.57–2.46 (m, 1 H), 2.38 (d, J = 1.4 Hz, 3 H), 1.50–1.37 (m, 2 H), 0.94 (d, J = 6.9 Hz, 3 H), 0.89 (s, 9 H), 0.84 (t, J = 7.4 Hz, 3 H), 0.05 (s, 3 H), 0.04 (s, 3 H).

^{13}C NMR (101 MHz, CDCl_3): δ = 144.09, 93.64, 76.49, 40.12, 28.01, 27.28, 26.06, 18.24, 16.60, 9.61, –4.15, –4.26.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{14}\text{H}_{29}\text{ONaSiI}$: 391.0930; found: 391.0919.

(2E,4E,6R,7S)-7-[(tert-Butyldimethylsilyloxy)-3,4,6-trimethylnona-2,4-dien-1-ol (38)

To a solution of boronic ether **16** (163 mg, 0.81 mmol, 2 equiv) in THF (1.5 mL) under argon was added TIOEt (0.05 mL, 0.73 mmol, 1.8 equiv) and degassed H_2O (0.15 mL) at r.t. and the resulting mixture was stirred for 5 min. To this mixture were added a solution of iodide **29** (150 mg, 0.41 mmol, 1 equiv) in THF (0.6 mL) and $\text{Pd}(\text{PPh}_3)_4$ (23 mg, 0.02 mmol, 0.05 equiv) and stirring was continued for 4 h. The mixture was filtered through Celite® and the pad rinsed with Et_2O .

The filtrate was concentrated under vacuum and the residue purified by column chromatography on silica gel (hexane/Et₂O, 30:1 to 6:1) to give adduct **38** (161 mg, 95%) as a colorless oil.

IR (thin film): 3314, 2957, 2929, 2857, 1462, 1377, 1254, 1102, 1073, 1060, 1006, 835, 773 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 5.70 (t, *J* = 6.3 Hz, 1 H), 5.59 (d, *J* = 9.5 Hz, 1 H), 4.31 (t, *J* = 6.0 Hz, 2 H), 3.47 (td, *J* = 6.1, 3.9 Hz, 1 H), 2.64 (dq, *J* = 13.6, 6.8, 3.9 Hz, 1 H), 1.83 (s, 3 H), 1.81 (d, *J* = 1.1 Hz, 3 H), 1.32–1.50 (m, 2 H), 1.22 (t, *J* = 5.5 Hz, 1 H), 0.97 (d, *J* = 6.9 Hz, 3 H), 0.90 (s, 9 H), 0.84 (t, *J* = 7.4 Hz, 3 H), 0.04 (s, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 139.64, 135.02, 130.75, 124.05, 77.36, 60.29, 37.74, 27.24, 26.07, 18.28, 16.98, 14.40, 14.27, 10.27, -4.09, -4.32.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₈H₃₆O₂NaSi: 335.2382; found: 335.2377.

(2E,4E,6R,7S)-7-[(*tert*-Butyldimethylsilyloxy)-3,4,6-trimethylno-2,4-dienal (**39**)]

To a solution of alcohol **38** (96 mg, 0.31 mmol) in CH₂Cl₂ (15 mL) was added MnO₂ (0.5 g, 6.15 mmol, 20 equiv) portionwise. The reaction was complete after stirring at r.t. for 1 h. The MnO₂ was removed by filtration through a pad of Celite® and the pad was rinsed with CH₂Cl₂. The filtrate was concentrated under reduced pressure and the obtained aldehyde **39** (91 mg, 96%) was used in the next step without purification.

IR (thin film): 2958, 2930, 2857, 1667, 1462, 1378, 1253, 1154, 1078, 1031, 836, 774 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 10.15 (d, *J* = 7.9 Hz, 1 H), 6.11 (dd, *J* = 27.0, 8.4 Hz, 2 H), 3.51 (td, *J* = 6.0, 3.9 Hz, 1 H), 2.71 (dq, *J* = 13.6, 6.8, 3.8 Hz, 1 H), 2.30 (d, *J* = 0.8 Hz, 3 H), 1.85 (d, *J* = 1.1 Hz, 3 H), 1.54–1.29 (m, 2 H), 1.00 (d, *J* = 6.9 Hz, 3 H), 0.89 (s, 9 H), 0.84 (t, *J* = 7.5 Hz, 3 H), 0.04 (d, *J* = 3.0 Hz, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 192.36, 158.48, 138.31, 135.10, 125.68, 77.11, 37.90, 27.95, 26.02, 18.23, 17.10, 14.43, 14.28, 9.88, -4.05, -4.39.

tert-Butyldimethyl[[(3S,4R,5E,7E)-4,6,7-trimethyldeca-5,7,9-trien-3-yl]oxy]silane (**40**)

To a solution of Ph₃PCH₃I (250 mg, 0.61 mmol, 2 equiv) in THF (2 mL) at 0 °C under argon was added NaN(SiMe₃)₂ (0.55 mL, 1 M in THF, 0.55 mmol, 1.8 equiv). After stirring for 20 min, a solution of aldehyde **39** (91 mg, 0.31 mmol, 1 equiv) in THF (1 mL) was added to the obtained yellow solution and stirring was continued for 2 h. After the reaction was complete, it was quenched by the addition of hexane and evaporated under vacuum until dry. The residue was purified by column chromatography on silica gel (hexane/Et₂O, 90:1) to give adduct **40** (76 mg, 84%) as a colorless oil.

IR (thin film): 2957, 2929, 2857, 1462, 1378, 1252, 1102, 1059, 1005, 833, 772 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 6.74 (ddd, *J* = 16.7, 10.9, 10.1 Hz, 1 H), 6.18 (d, *J* = 11.0 Hz, 1 H), 5.68–5.60 (m, 1 H), 5.23 (dd, *J* = 16.7, 1.8 Hz, 1 H), 5.09 (dd, *J* = 10.1, 1.9 Hz, 1 H), 3.48 (td, *J* = 6.1, 3.9 Hz, 1 H), 2.66 (dq, *J* = 13.6, 6.8, 3.9 Hz, 1 H), 1.92 (s, 3 H), 1.84 (d, *J* = 1.1 Hz, 3 H), 1.50–1.33 (m, 2 H), 0.97 (d, *J* = 6.8 Hz, 3 H), 0.90 (s, 9 H), 0.84 (t, *J* = 7.4 Hz, 3 H), 0.05 (d, *J* = 1.0 Hz, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 138.79, 135.34, 134.19, 131.25, 125.58, 116.56, 77.40, 37.92, 27.23, 26.07, 18.29, 16.98, 14.41, 14.36, 10.27, -4.09, -4.31.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₉H₃₆ONaSi: 331.2433; found: 331.2448.

tert-Butyldimethyl[[(3S,4R,5E,7E,9E)-4,6,7-trimethyl-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)deca-5,7,9-trien-3-yl]oxy]silane (**45**)

A mixture of **40** (54 mg, 0.17 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (0.059 mL, 0.35 mmol, 2 equiv) and Hoveyda–Grubbs 1st generation catalyst (16 mg, 0.03 mmol, 0.15 equiv) in CH₂Cl₂ (0.7 mL) was heated at 35–40 °C with stirring under argon for 3 h. After completion, the reaction was loaded onto a silica gel column and eluted with hexane/Et₂O (50:1 to 35:1) to give adduct **45** (55 mg, 72%).

IR (thin film): 2976, 2958, 2930, 2857, 1606, 1379, 1350, 1257, 1143, 850 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.43 (dd, *J* = 17.3, 11.0 Hz, 1 H), 6.24 (d, *J* = 10.9 Hz, 1 H), 5.71 (d, *J* = 9.0 Hz, 1 H), 5.56 (d, *J* = 17.3 Hz, 1 H), 3.48 (td, *J* = 5.9, 4.1 Hz, 1 H), 2.67 (dq, *J* = 13.6, 6.8, 4.1 Hz, 1 H), 1.99 (d, *J* = 0.6 Hz, 3 H), 1.83 (d, *J* = 1.0 Hz, 3 H), 1.41 (m, 2 H), 1.28 (s, 12 H), 0.97 (d, *J* = 6.8 Hz, 3 H), 0.89 (s, 9 H), 0.84 (t, *J* = 7.4 Hz, 3 H), 0.04 (s, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 146.75, 142.34, 135.50, 132.72, 127.13, 83.20, 77.32, 38.00, 27.25, 26.06, 24.92, 18.27, 16.92, 14.81, 14.41, 10.16, -4.10, -4.32.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₂₅H₄₇O₃NaSiB: 457.3285; found: 457.3282.

(2Z,4E,6E,8E,10R,11S)-11-[(*tert*-Butyldimethylsilyloxy)-3,7,8,10-tetramethyltrideca-2,4,6,8-tetraenitrile (**41**)]

To a solution of boronic ether **45** (27 mg, 0.06 mmol, 1 equiv) in THF (0.9 mL) under argon was added TiOEt (0.01 mL, 0.14 mmol, 2.3 equiv) and degassed H₂O (0.09 mL) at r.t. and the mixture stirred for 5 min. Next, a solution of iodide **1** (16 mg, 0.08 mmol, 1.4 equiv) in THF (1 mL) and Pd(PPh₃)₄ (7 mg, 0.006 mmol, 0.1 equiv) were added and stirring was continued for 1 h. The reaction mixture was filtered through Celite® and the pad was rinsed with Et₂O. The filtrate was concentrated under vacuum. The residue was purified by column chromatography on silica gel (hexane/Et₂O, 100:1 to 80:1) to give adduct **41** (15 mg, 67%) as a colorless oil.

IR (thin film): 2957, 2929, 2856, 2209, 1591, 1378, 1360, 1252, 1078, 1029, 961, 835, 773 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.00 (dd, *J* = 15.0, 11.1 Hz, 1 H), 6.84 (d, *J* = 15.0 Hz, 1 H), 6.35 (d, *J* = 11.1 Hz, 1 H), 5.79 (d, *J* = 9.5 Hz, 1 H), 5.07 (s, 1 H), 3.50 (td, *J* = 6.0, 3.9 Hz, 1 H), 2.69 (dq, *J* = 13.6, 6.8, 3.9 Hz, 1 H), 2.07 (d, *J* = 1.3 Hz, 3 H), 2.00 (s, 3 H), 1.87 (d, *J* = 1.0 Hz, 3 H), 1.33–1.51 (m, 2 H), 0.99 (d, *J* = 6.8 Hz, 3 H), 0.90 (s, 9 H), 0.85 (t, *J* = 7.4 Hz, 3 H), 0.05 (s, 6 H).

¹³C NMR (101 MHz, CDCl₃): δ = 156.82, 144.25, 135.41, 133.96, 133.73, 128.79, 124.49, 117.63, 94.91, 77.32, 38.02, 27.50, 26.06, 19.59, 18.28, 17.09, 14.78, 14.40, 10.13, -4.07, -4.32.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₂₃H₃₉NONaSi: 396.2699; found: 396.2695.

Funding Information

This work was supported by the Academy of Finland (project number 266369) and (to O.V.K.) the FP7 InnovaBalt project (contract Nr.316149). The authors would like to acknowledge the networking contribution by COST Action CM1407 “Challenging organic syntheses

inspired by nature – from natural products chemistry to drug discovery”.

Acknowledgment

The authors would like to acknowledge Tiia Seppä for HRMS measurements.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0037-1610387>.

References

- (1) (a) Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K. *J. Am. Chem. Soc.* **1986**, *108*, 2780. (b) Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K.; Koseki, K. *J. Org. Chem.* **1988**, *53*, 3930. (c) Calyculins E–H: Matsunaga, S.; Fujiki, H.; Sakata, D.; Fusetani, N. *Tetrahedron* **1991**, *47*, 2999.
- (2) Dumdei, E. J.; Blunt, J. W.; Munro, M. H. G.; Pannell, L. K. *J. Org. Chem.* **1997**, *62*, 2636.
- (3) Matsunaga, S.; Wakimoto, T.; Fusetani, N. *J. Org. Chem.* **1997**, *62*, 2640.
- (4) Matsunaga, S.; Wakimoto, T.; Fusetani, N.; Sukanuma, M. *Tetrahedron Lett.* **1997**, *38*, 3763.
- (5) Steube, K. G.; Meyer, C.; Proksch, P.; Supriyono, A.; Sumaryono, W.; Drexler, H. G. *Anticancer Res.* **1998**, *18*, 129.
- (6) Fu, X.; Schmitz, F. J.; Kelly–Borges, M.; McCready, T. L.; Holmes, C. F. B. *J. Org. Chem.* **1998**, *63*, 7957.
- (7) Wakimoto, T.; Egami, Y.; Abe, I. *Nat. Prod. Rep.* **2016**, *33*, 751.
- (8) Fagerholm, A. E.; Habrant, D.; Koskinen, A. M.P. *Mar. Drugs* **2010**, *8*, 122.
- (9) Evans, D. A.; Gage, J. R.; Leighton, J. L. *J. Am. Chem. Soc.* **1992**, *114*, 9434.
- (10) Tanimoto, N.; Gerritz, S. W.; Sawabe, A.; Noda, T.; Filla, S. A.; Masamune, S. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 673.
- (11) Yokokawa, F.; Hamada, Y.; Shioiri, T. *Chem. Commun.* **1996**, 871.
- (12) Smith, A. B. III; Friestad, G. K.; Duan, J. J.–W.; Barbosa, J.; Hull, K. G.; Iwashima, M.; Qiu, Y.; Spoons, P. G.; Bertounesque, E.; Salvatore, B. A. *J. Org. Chem.* **1998**, *63*, 7596.
- (13) Ogawa, A. K.; Armstrong, R. W. *J. Am. Chem. Soc.* **1998**, *121*, 12435.
- (14) Anderson, O. P.; Barrett, A. G. M.; Edmunds, J. J.; Hachiya, S.–I.; Hendrix, J. A.; Horita, K.; Malecha, J. W.; Parkinson, C. J.; VanSickle, A. *Can. J. Chem.* **2001**, *79*, 1562.
- (15) Fragment A: (a) Koskinen, A. M.P.; Chen, J. *Tetrahedron Lett.* **1991**, *32*, 6977. (b) Passiniemi, M.; Koskinen, A. M. P. *Synthesis* **2010**, 2816. Fragment B: (c) Koskinen, A. M.P.; Pihko, P. M. *Tetrahedron Lett.* **1994**, *35*, 7417. (d) Pihko, P. M.; Koskinen, A. M. P. *J. Org. Chem.* **1998**, *63*, 92. Fragment C: (e) Habrant, D.; Koskinen, A. M. P. *Org. Biomol. Chem.* **2010**, *8*, 4364.
- (16) Pihko, P. M.; Koskinen, A. M. P. *Synlett* **1999**, 1966.
- (17) Barrett, A. G. M.; Edmunds, J. J.; Hendrix, J. A.; Horita, K.; Parkinson, C. J. *J. Chem. Soc., Chem. Commun.* **1992**, 1238.
- (18) (a) Yokokawa, F.; Hamada, Y.; Shioiri, T. *Tetrahedron Lett.* **1993**, *34*, 6559. (b) Matsubara, J.; Nakao, K.; Shioiri, T. *Tetrahedron Lett.* **1992**, *33*, 4187.
- (19) Scarlato, G. R.; DeMattei, J. A.; Chong, L. S.; Ogawa, A. K.; Lin, M. R.; Armstrong, R. W. *J. Org. Chem.* **1996**, *61*, 6139.
- (20) Negishi, E. *Bull. Chem. Soc. Jpn.* **2007**, *80*, 233.
- (21) Ronson, T. O.; Taylor, R. J. K.; Fairlamb, I. J. S. *Tetrahedron* **2015**, *71*, 989.
- (22) Heravi, M. M.; Hashemi, E.; Azimian, F. *Tetrahedron* **2014**, *70*, 7.
- (23) Heravi, M. M.; Hashemi, E. *Tetrahedron* **2012**, *68*, 9145.
- (24) Kosugi, M.; Fugami, K. *J. Organomet. Chem.* **2002**, 653, 50.
- (25) Negishi, E. *Angew. Chem. Int. Ed.* **2011**, *50*, 6738.
- (26) Beletskaya, I. P.; Cheprakov, A. V. *Chem. Rev.* **2000**, *100*, 3009.
- (27) Miyaura, N.; Yamada, K.; Suzuki, A. *Tetrahedron Lett.* **1979**, *20*, 3437.
- (28) Corey, E. J.; Katzenellenbogen, J. A.; Posner, G. H. *J. Am. Chem. Soc.* **1967**, *89*, 4245.
- (29) Betzer, J.–F.; Delalogue, F.; Muller, B.; Pancrazi, A.; Prunet, J. *J. Org. Chem.* **1997**, *62*, 7768.
- (30) Jung, M. E.; Light, L. A. *Tetrahedron Lett.* **1982**, *23*, 3851.
- (31) Zhang, H. X.; Guibe, F.; Balavoine, G. *J. Org. Chem.* **1990**, *55*, 1857.
- (32) Huang, Z.; Negishi, E. *Org. Lett.* **2006**, *8*, 3675.
- (33) (a) Cornil, J.; Echeverria, P.–G.; Phansavath, P.; Ratovelomanana-Vidal, V.; Guérinot, A.; Cossy, J. *Org. Lett.* **2015**, *17*, 948. (b) Madden, K. S.; David, S.; Knowles, J. P.; Whiting, A. *Chem. Commun.* **2015**, *51*, 11409. (c) Jeffery, T. *Tetrahedron Lett.* **1985**, *26*, 2667.
- (34) Desai, N. B.; McKelvie, N.; Ramirez, F. *J. Am. Chem. Soc.* **1962**, *84*, 1745.
- (35) Roush, W. R.; Moriarty, K. J.; Brown, B. B. *Tetrahedron Lett.* **1990**, *31*, 6509.
- (36) Kim, K.; Lauher, J. W.; Parker, K. A. *Org. Lett.* **2012**, *14*, 138.
- (37) Sofiyev, V.; Navarro, G.; Trauner, D. *Org. Lett.* **2008**, *10*, 149.
- (38) Jacobsen, M. F.; Moses, J. E.; Adlington, R. M.; Baldwin, J. E. *Tetrahedron* **2006**, *62*, 1675.
- (39) Zeng, X.; Qian, M.; Hu, Q.; Negishi, E. *Angew. Chem. Int. Ed.* **2004**, *43*, 2259.
- (40) Källström, S.; Erkkilä, A.; Pihko, P. M.; Sjöholm, R.; Sillanpää, R.; Leino, R. *Synlett* **2005**, 751.
- (41) Corey, E. J.; Fuchs, P. L. *Tetrahedron Lett.* **1972**, *13*, 3769.
- (42) Hart, D. W.; Blackburn, T. F.; Schwartz, J. J. *J. Am. Chem. Soc.* **1975**, *97*, 679.
- (43) Dale, J. A.; Dull, D. L.; Mosher, H. S. *J. Org. Chem.* **1969**, *34*, 2543.
- (44) Ward, D. E.; Rhee, C. K. *Tetrahedron Lett.* **1991**, *32*, 7165.
- (45) (a) Crossman, J. S.; Perkins, M. V. *J. Org. Chem.* **2006**, *71*, 117. (b) Brown, H. C.; Bhat, K. S. *J. Am. Chem. Soc.* **1986**, *108*, 5919. (c) Kalaitzakis, D.; Smonou, I. *Eur. J. Org. Chem.* **2012**, 43.
- (46) Moure, A. L.; Gómez Arrayás, R.; Cárdenas, D. J.; Alonso, I.; Carretero, J. C. *J. Am. Chem. Soc.* **2012**, *134*, 7219.
- (47) Mitsudo, T.; Fischetti, W.; Heck, R. F. *J. Org. Chem.* **1984**, *49*, 1640.
- (48) Okada, A.; Watanabe, K.; Umeda, K.; Miyakado, M. *Agric. Biol. Chem.* **1991**, *55*, 2765.
- (49) Zurwerra, D.; Gertsch, J.; Altmann, K.–H. *Org. Lett.* **2010**, *12*, 2302.
- (50) Yang, Q.; Draghici, C.; Njardarson, J. T.; Li, F.; Smith, B. R.; Das, P. *Org. Biomol. Chem.* **2014**, *12*, 330.
- (51) Placzek, A. T.; Gibbs, R. A. *Org. Lett.* **2011**, *13*, 3576.
- (52) Paterson, I.; Anderson, E. A.; Dalby, S. M.; Lim, J. H.; Maltas, P.; Loiseleur, O.; Genovino, J.; Moessner, C. *Org. Biomol. Chem.* **2012**, *10*, 5861.